SafeCode Drug Technologies Corp. Granted Eligibility Status by the Depository Trust Company
JERUSALEM, October 16, 2012 /PRNewswire/ --
SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of a patent-pending voice recognition technology that reduces the risks of errors during of administration of prescription medications, announced today that the company has been granted eligibility status by the Depository Trust Company (DTC). The DTC provides banks, brokerage firms and other institutions with an efficient means of moving securities and settling trades electronically.
"SafeCode Drug Technologies has acquired the patent-pending voice recognition technology that can significantly reduce the risks of errors of administering the wrong medication," said Joel Klopfer, CEO of SafeCode Drug Technologies. "We are excited to being able in the future to bring this potentially life-saving technology to the market."
About SafeCode Drug Technologies
SafeCode Drug Technologies is the developer of a patent-pending voice recognition technology that provides an essential degree of security that can effectively prevent unauthorized administration of a prescription medication.
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of SafeCode Drug Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. SafeCode Drug Technologies Corp. public filings may be viewed at http://www.sec.gov.
SOURCE Safecode Drug Technologies Corp.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.